EyePoint Pharmaceuticals, Inc. announced on January 28, 2021 that the first patient has been dosed in their Phase 1 clinical trial of EYP-1901. EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wAMD). It is the newest of several sustained delivery drugs under study, this one promising to extend [Read More]
Category: Therapies, Treatments, and Procedures
Looking Forward to 2021
Even the most optimistic person will admit that 2020 was a 365-day slog through dangers, disasters, and disappointments. In a year that offered little relief, considering that its famous number might have been expected to boost our spirits with good news about vision. And that’s why it might help us to look ahead at some [Read More]
Anti-VEGF treatment maintains acuity over 10 years
Patients receiving continuous injections of anti-VEGF drugs for treatment of wet age related macular degeneration (wAMD) can take comfort in knowing that they are keeping their initial visual acuity long term. As reported in the September 29 issue of Ophthalmology Retina, the LATAR study found that 293 eyes not only maintained their original visual acuity, [Read More]
Light Therapy Showing Success As Retinal Treatment
According to an article in the August 6, 2020 edition of Ophthalmology Times, a procedure called photobiomodulation (PBM) has had recent success in treating eye diseases such as AMD, retinopathy of prematurity, and diabetic macular edema. PBM, or low-level light therapy, is the application of monochromatic light to a part of the body with the [Read More]
New Drug For Wet AMD Should Be Used With Caution
Beovu (brolucizumab) for wet AMD is the newest anti-VEGF drug on the market. It has been shown to be an effective and long-lasting inhibitor of blood vessel development (neovascularization) in the retina. The drug’s manufacturer has, however, been recently investigating incidences of severe intraocular inflammation (vasculitis) and retinal artery occlusion that were reported after their product [Read More]